The Daily Toke

April 23, 2026

# Federal Marijuana Rescheduling: A Historic Shift in Drug Policy

Acting Attorney General Todd Blanche signed an executive order Thursday reclassifying state-licensed medical marijuana from Schedule I to Schedule III—the most significant federal cannabis policy change in decades. The move comes more than four months after President Trump issued an executive order directing the Department of Justice to expedite the rescheduling process. Under the new order, state-regulated medical marijuana and FDA-approved cannabis products immediately shift to Schedule III, the same category as ketamine and Tylenol with codeine. Beginning June 29, the Drug Enforcement Administration will hold expedited administrative hearings to consider broader rescheduling of marijuana from Schedule I to Schedule III. The effort marks a dramatic reversal from the Biden administration's stalled attempt, which faced legal challenges and internal delays that frustrated cannabis advocates.

🚀 THIS IS COOL What makes this shift genuinely consequential is what it unlocks. Researchers will finally be able to conduct rigorous studies on cannabis safety and efficacy without the research barriers imposed by Schedule I classification. Scientists from the University of Michigan noted earlier this year that Schedule I status has severely limited cannabis research even as Americans' access to the drug has exploded—nearly 80 percent of Americans now live in a county with at least one legal marijuana dispensary. State-licensed medical marijuana operators also gain a major financial benefit: they can now deduct business expenses on federal taxes, a relief long denied under Internal Revenue Service code 280E. The order eases the path for state regulatory agencies to provide cannabis for research purposes, and Reps. Dina Titus (D-NV) and Ilhan Omar (D-MN) filed a companion bill authorizing $150 million in new funding to support cannabis research.

💰 MONEY MOVES Cannabis industry stocks soared on the announcement. Tilray Brands jumped 14.2 percent on rumors of imminent rescheduling, with trading volume ballooning to 28 million shares. Canopy Growth climbed 21.1 percent, and U.S.-based Curaleaf surged 26.3 percent. The AdvisorShares Pure US Cannabis ETF shot up 19.4 percent, though it remains a fraction of its February 2021 peak of $55.05. Canadian-licensed producers like Tilray and Canopy have lost billions over the past decade, and the rescheduling opens pathways to banking services and capital access long restricted to Schedule I operators. The tax deduction benefit applies retroactively for past tax years, meaning state-licensed operators may recover substantial federal tax liabilities.

The reclassification does not legalize recreational marijuana under federal law—a critical distinction. It simply shifts how medical marijuana is regulated and removes certain research barriers that have constrained science for over 50 years. Virginia lawmakers rejected Gov. Abigail Spanberger's proposed amendments to recreational marijuana legalization legislation this week, sending bills back to her for signature or veto, showing that state-level legalization debates continue independently of federal rescheduling. California advanced a bill allowing marijuana dispensaries to offer drive-thru windows. The federal shift, however, legitimizes the 40 states that have adopted medical marijuana programs, many operating in legal gray zones since 1996 when California became the first state to legalize medical cannabis.

Public support has made this politically feasible. A new poll shows nearly 60 percent of Americans favor legalizing marijuana overall, with majority support across party lines. Eighty-four percent want legalization of medical cannabis for patients. This baseline of public acceptance mirrors a broader cultural shift: the share of Americans who regularly use marijuana has doubled over the past 13 years, and support for legalization has doubled since 2000. Trump himself expressed frustration with the pace of rescheduling, telling podcaster Joe Rogan over the weekend that "they're slow-walking me," and sources told CNN that White House officials considered announcing the action on April 20 but were advised against the optics.

🤔 THINK ABOUT IT The federal government kept cannabis in Schedule I—the most restrictive category reserved for drugs with no accepted medical use and high abuse potential—for over 50 years, despite the Shafer Commission recommending decriminalization back in 1970. Meanwhile, alcohol kills approximately 95,000 Americans annually, prescription opioids kill 16,000-plus per year, and cannabis has zero recorded overdose deaths in human history. If the stated goal was protecting public health, which substance actually warranted Schedule I status all along?

April 23, 2026

# Cannabis Business Briefing | April 23, 2026

Cannabis legalization continues its rapid expansion across the United States, with 24 states plus Washington D.C. now allowing recreational use as of early 2026, while 40 states plus D.C. permit medical cannabis. The market landscape reflects this growth: California remains the world's largest cannabis market with $1.835 billion in mid-year sales and over $275 million in tax revenue, while newer recreational markets like Arizona have become among the fastest-growing in the nation since launching sales in 2021. 💰 MONEY MOVES These expanding legal markets represent a fundamental shift in how states approach cannabis taxation and regulation—a direct contrast to decades of federal prohibition that generated billions in enforcement spending without reducing consumption.

The federal government's position on cannabis is undergoing significant movement. The Trump administration is reportedly ready to advance marijuana rescheduling, a process initiated by presidential executive order four months ago but previously stalled. Concurrently, the House is considering multiple legislative approaches to cannabis policy: Representatives Dina Titus (D-NV) and Ilhan Omar (D-MN) filed a bill authorizing $150 million to support marijuana research and allowing state regulatory agencies to provide cannabis for studies, while California's Assembly advanced a bill permitting dispensaries to operate drive-thru windows subject to local approval. 🚀 THIS IS COOL These policy shifts acknowledge what scientists have documented for years—that cannabis contains over 500 chemical compounds with therapeutic potential, including cannabidiol (CBD) and other cannabinoids researchers are actively studying for applications ranging from chronic pain to seizure management.

Hemp-derived THC products face regulatory uncertainty despite their legal status under the 2018 Farm Bill. Republican lawmakers, including House Oversight Committee Chairman James Comer (R-KY), have filed amendments to the 2026 Farm Bill to delay the scheduled recriminalization of hemp products until November 2027. Representative Andy Barr (R-KY) proposed creating a regulatory framework "that protects children, bans synthetics, and ensures that any products on the market place are of American origin," though his amendment was withdrawn for undisclosed reasons. The core issue: the Trump administration's late-2025 legislation redefined hemp to permit only products containing 0.4 milligrams of total THC per container after November 12, effectively eliminating the existing legal intoxicating hemp market and the businesses operating within it.

Public support for cannabis normalization has reached a tipping point. A new poll shows nearly six in ten Americans favor legalization, with majority support crossing party lines—and 84 percent support legalizing medical cannabis access for patients. This represents genuine consensus building, yet 🤔 THINK ABOUT IT while federal law maintains cannabis as Schedule I (deemed to have no medical value and high abuse potential), alcohol remains legal despite killing approximately 95,000 Americans annually, and prescription opioids continue killing over 16,000 people per year, with zero recorded overdose deaths from cannabis in human history. The classification has persisted for over 50 years since Nixon's 1970 Controlled Substances Act, despite his own Shafer Commission recommending decriminalization.

New Jersey's cannabis market exemplifies the emerging infrastructure of legal distribution: the state's Cannabis Regulatory Commission maintains an online dispensary directory for both recreational and medicinal (ATC) consumers and actively encourages licensed operators to register for inclusion. States like Connecticut have intentionally structured their licensing programs around social equity, prioritizing permits for those impacted by past cannabis criminalization. 💰 MONEY MOVES These infrastructure investments—dispensary networks, regulatory agencies, tax collection systems—represent hundreds of millions in legitimate economic activity that previously flowed through unregulated markets or enforcement budgets. The cannabis business ecosystem now includes cultivation licensing, testing facilities, retail operations, delivery services, and ancillary industries, creating employment and tax revenue streams in nearly half the nation.

The regulatory landscape remains fragmented between state legalization and federal scheduling, creating ongoing challenges for interstate commerce, banking, and research. Yet the direction is unmistakable: normalization is accelerating through consumer preference, legislative action, and market forces—not through relaxation of enforcement, but through active state regulation, licensing, and taxation frameworks that treat cannabis as a commercial product worthy of the same oversight applied to alcohol, tobacco, or pharmaceuticals.

April 23, 2026

Federal lawmakers are intensifying pressure to crack down on hemp-derived THC products, a move that threatens to upend a $28 billion industry that has grown rapidly in the legal gray space created by the 2018 Farm Bill. Congress is pushing restrictions after sustained pressure from states and the marijuana industry itself, with federal officials targeting what they describe as a "loophole" in hemp THC regulations. The push reflects a broader tension: while traditional cannabis remains Schedule I at the federal level, hemp-derived products containing THC have flourished in states where cannabis remains illegal, creating a patchwork of conflicting state and federal policy. 💰 MONEY MOVES The potential congressional restrictions are sending companies scrambling to adjust their business models, as the hemp-derived market has become a significant revenue generator for retailers, manufacturers, and producers across the country.

Texas exemplifies the front-line conflict. State authorities have launched a THC flower crackdown, even as hemp-derived products continue flowing into the state under federal hemp law protections. This creates confusion for consumers and retailers alike—the same plant material can be legal under federal hemp regulations but illegal under state law depending on how it's classified and marketed. Similar contradictions are playing out in South Carolina and Missouri, where state governments are threatening their own bans on hemp-derived products even as federal policy remains unclear about whether a comprehensive prohibition is coming.

The pharmaceutical and alcohol industries have significant financial stakes in cannabis prohibition. Prescription opioids, which are Schedule II despite killing over 16,000 Americans annually, compete with cannabis for pain management dollars. Alcohol, which kills approximately 95,000 Americans per year, faces no Schedule I classification despite being legal. 🤔 THINK ABOUT IT When lawmakers cite "protecting children" as the rationale for cracking down on a plant with zero recorded overdose deaths in human history, while alcohol remains the number-one drug-related killer of teenagers, what problem are they actually trying to solve?

💰 MONEY MOVES A federal hemp crackdown could restore pricing power to traditional cannabis markets in states where it's legal, potentially benefiting established marijuana businesses that have lobbied for stricter federal hemp regulations. This creates an unusual alliance: state-legal cannabis companies pushing for federal restrictions on their hemp-derived competitors. The economic consequence is stark—thousands of small hemp businesses could face closure, while larger cannabis corporations gain market consolidation.

Veterans represent a particularly vulnerable population in this regulatory shuffle. Many use legally available hemp-derived THC products for PTSD, chronic pain, and anxiety management. If federal restrictions eliminate these products without creating federal access pathways for veterans, they'll face the choice between unregulated black market products or returning to prescription pharmaceuticals with documented addiction risks. The Department of Veterans Affairs has been cautiously studying cannabis for PTSD, but Schedule I classification continues to block robust clinical research that could establish evidence-based protocols.

The hemp crackdown timeline remains uncertain, but the momentum is real. Congressional interest is documented, state-level enforcement is accelerating, and industry players are preparing for significant regulatory change. Whether this results in a full federal ban, targeted THC potency restrictions, or continued legal ambiguity will reshape an entire sector—and determine access for millions of Americans, including veterans, who have built their wellness practices around legal hemp products.

April 23, 2026

# THC in Science: Clinical Trials Push Past Uncertainty

Researchers across the country are launching rigorous clinical trials to answer one of medicine's most contentious questions: does marijuana actually work? UCHealth and other major medical institutions have begun systematic studies designed to move cannabis beyond anecdotal evidence and into evidence-based practice. The timing reflects a broader shift in the scientific community—after decades of Schedule I restrictions that made research nearly impossible, investigators now have clearer pathways to study THC and CBD compounds at scale. What they're finding is messier than either advocates or opponents expected: some conditions show genuine promise, while others remain stubbornly unproven.

The evidence landscape is genuinely mixed. A comprehensive review published in December 2025 found little evidence supporting medical cannabis use across most conditions, a sobering assessment that matched findings from Newswise and other systematic reviewers. Yet simultaneously, 🚀 THIS IS COOL a scientific review published in January 2026 showed that CBD compounds have "substantial promise" in combating tumor growth from cancer, suggesting that cannabinoids may have genuine therapeutic mechanisms we're only beginning to understand. The challenge is that "cannabis" is not one drug—it's a plant with over 100 active compounds, each with different effects, potencies, and medical profiles. Lumping them together in research or policy makes as much sense as treating "plants" as a single medicine.

Chronic pain is where the real scientific tension emerges. 🚀 THIS IS COOL Recent Science Daily reporting examined what cannabis actually does for chronic pain sufferers, moving past generalizations toward mechanism-based understanding. Patients report relief where prescription opioids have failed or created dependency—a documented pattern that matters given that opioid painkillers kill over 16,000 Americans annually, compared to zero recorded cannabis overdose deaths in human history. Yet the clinical evidence remains fragmented, partly because decades of Schedule I classification meant researchers simply weren't studying it. Now that trials are ramping up, the baseline question shifts from "does it work?" to "for whom, in what doses, and through which mechanisms?"

🤔 THINK ABOUT IT We've spent fifty years restricting research on a zero-overdose-death plant while alcohol kills roughly 95,000 Americans per year and remains completely legal. The FDA approves pharmaceuticals based on clinical trials. Cannabis deserves the same rigor—which is precisely what these new trials are attempting to provide. The scientific community isn't hiding results; it's finally being allowed to conduct them systematically.

The real story isn't whether cannabis works—it's that we're finally asking the question properly. Britannica's recent overview of the medical marijuana debate captures the genuine complexity: there are legitimate pros, legitimate cons, and a genuine need for evidence rather than ideology on either side. The trials underway at UCHealth and similar institutions represent science working as it should: skeptical, methodical, and willing to follow data wherever it leads. Whether that data vindicates or challenges current assumptions, at least we'll have answers based on evidence rather than prohibition-era assumptions.

April 23, 2026

Federal marijuana rescheduling is officially underway following Acting Attorney General Todd Blanche's announcement Thursday, more than four months after President Trump signed an executive order directing the Department of Justice to move cannabis from Schedule I to Schedule III of the Controlled Substances Act. The rollout happens in two phases: state-licensed medical cannabis products and FDA-approved marijuana immediately shift to Schedule III, while a broader rescheduling hearing process begins June 29. DEA Administrator Terry Cole stated the agency is "expeditiously moving forward with the administrative hearing process—bringing consistency and oversight to an area that has lacked both," signaling an effort to restart momentum after litigation stalled Biden-era proceedings.

💰 MONEY MOVES The financial implications are substantial for state-licensed cannabis operators. Rescheduling to Schedule III removes the federal tax deduction barrier imposed under IRS code 280E, allowing medical marijuana businesses to claim deductions they've been blocked from for years—potentially including retroactive relief for past tax years if the Treasury Department acts on DOJ's recommendation. While rescheduling doesn't federally legalize cannabis, it removes research barriers that have constrained scientific investigation and opens pathways for federal tax relief that state-legal businesses have been denied despite operating in full compliance with state law. Companies serving both medical and recreational markets may initially only access relief for their medical divisions, pending clarification from federal agencies.

Meanwhile, Republican lawmakers are filing competing amendments to the 2026 Farm Bill that would preserve the legal hemp market beyond November's scheduled ban on products containing more than 0.4 milligrams of total THC per container. House Oversight Chairman James Comer (R-KY) is proposing to delay the ban until November 2027, while Rep. Andy Barr (R-KY) submitted a separate framework to "preserve the lawful hemp market while creating a regulatory framework that protects children, bans synthetics, and ensures that any products on the market place are of American origin"—though Barr withdrew his amendment Wednesday for undisclosed reasons. The Rules Committee will decide next week whether these proposals qualify for House floor votes, after the Agriculture Committee previously ruled a similar delay amendment non-germane to the legislation.

🚀 THIS IS COOL On the research side, the Senate Veterans' Affairs Committee scheduled a hearing for next week on bipartisan legislation to establish a new psychedelics office within the Department of Veterans Affairs. The Veterans Health Administration Novel Therapeutics Preparedness Act, led by Sen. Tim Sheehy (R-MT) and cosponsored by Senators Tammy Duckworth (D-IL), Ruben Gallego (D-AZ), and John Boozman (R-AR), would streamline studies into psilocybin, ibogaine, MDMA, and LSD for treating PTSD, treatment-resistant depression, traumatic brain injury, and chronic pain in veterans. The bill coordinates with Trump's executive order on psychedelics expansion and recognizes that "emerging therapeutic interventions, including certain psychedelic-assisted therapies under evaluation by the Food and Drug Administration, may significantly alter the treatment landscape" for conditions affecting the veteran population.

🤔 THINK ABOUT IT These developments reflect a broader shift in federal drug policy recognition: Schedule I has protected cannabis from research for over 50 years despite the Shafer Commission's 1970 recommendation for decriminalization, while hemp-derived THC products have operated in legal gray zones for years despite zero recorded overdose deaths. Veterans and patients with qualifying conditions now face expanding federal pathways for both cannabis and psychedelic research—treatments showing clinical promise that have never caused a single recorded overdose death, unlike alcohol (95,000 deaths annually) and prescription opioids (16,000+ deaths annually), both fully legal and federally regulated. The question isn't whether these substances work; it's why research access was blocked for so long.